Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Also remember that organic sales growth in the first half of 2023 was very strong at 11% |
| But I would say we have had the good fortune across the board to be able to get some price across all those different vehicles in service |
| I am proud of how our teams executed to deliver robust financial results with performance that all met or exceeded guidance |
| In fact, our execution throughout the year allowed us to raise guidance twice |
| All of them have the profile of deals that we like, strategically relevant, accretive to our business, really solid ROIs over time |
| And we set up 2024 with another solid 90% conversion rate and free cash flow growth |
| Backlog remains robust led by an improved capital equipment landscape |
| And we significantly strengthened our balance sheet as we paid down $1 billion in debt since the beginning of the fourth quarter |
| And the result was we exceeded our cash flow expectations by a good margin |
| We were able to deliver 95% conversion, which we were very proud of |
| MIM Software is really the best in the world |
| We’ve assembled a strong world class leadership team |
| Obviously, GE HealthCare, well positioned on the diagnostics side |
| And so we are quite excited about |
| Our outlook reflects an improved capital equipment landscape |
| It also reflects continued strength on top of 2 consecutive years of high single-digit organic sales growth |
| Our latest survey showed improved financial optimism and capital budget outlook versus the last survey in October |
| Global procedures remain strong, which we believe all of this points to a constructive setup for the year |
| So, that’s the part that we watch is that customers’ health, particularly in the United States is improving and the procedures growth is on the rise |
| At the same time, demand is strong, meaning the procedures of patients coming in, either from orthopedic, cardiovascular, neuro, I mean across the board |
| But by and large, we feel good about how we are thinking about 2024 |
| Order dollars continue to outpace sales, leading to a total company book-to-bill of 1.05x, up sequentially from 1.03x due to healthy product orders, including equipment |
| First of all, hospital profitability is robust |
| And so the dynamic that Pete described is one that we’re working through, and I think presents a nice opportunity for the second half of the year and beyond |
| Sequentially, margin improved 70 basis points, supported by seasonally higher volume while we expanded our investments in future innovation |
| The lean methodology is at the foundation of our productivity, yielding strong performance in the fourth quarter with improvements in logistics, sourcing and services |
| Our teams came together to increase on-time delivery to our customers by 11% year-over-year with lean actions improving demand forecast accuracy, supplier planning and lead times |
| We also saw past-due backlog efficiency with a greater than 50% improvement year-over-year in Imaging alone |
| The margin expansion guide was really impressive, 50 to 80 basis points |
| No, I would just – I think you covered it, Jay, other than the fact to say that, look, we were super pleased with the order book performance |
| Statement |
|---|
| Organic revenue was down 2% year-over-year due to the impact of lower volume tied to a challenging comparison for the same period last year |
| And really what this comes down to is the challenging comp that we saw in Q1 of last year |
| We expect year-over-year organic revenue growth and adjusted EBIT margin in the first quarter to be the lowest of the year |
| Segment EBIT margin declined year-over-year due to investments such as the Caption Health artificial intelligence integration |
| PCS margin decreased 320 basis points compared to last year driven by investments and onetime favorability that we experienced in the prior year |
| Free cash flow of $956 million was down slightly year-over-year |
| So we’re actually expecting our growth to be negative year-over-year |
| These costs were allocated based on revenue and equated to approximately 100 basis points of margin headwind for each segment |
| And the first quarter will be lower than the second quarter |
| Overall, as I said in my prepared remarks, the first half will be lower than the second half |
| And I just remind everybody, unlike other drugs where you can just deliver in any center, these products have a half-life, which means the moment you make them, they are degrading |
| I would note that we expect a foreign exchange headwind to revenue of less than 1% in 2024 |
| We generated free cash flow of $956 million during the fourth quarter, down $31 million year-over-year with standalone cash outflows |
| On China, we expect a decline in the first half |
| Can we just touch on China again, just to clarify one of the statements earlier? You said you are expecting no growth, but also negative growth in the first half |
| become photon counting? Peter Arduini I think 5 years is a little bit optimistic |
| This year-over-year margin decline was partially mitigated by cost productivity as we drove standardization and commonality across our platforms |
| Pete talked about one, but frankly, it’s a volatile world that we’re living in |
| Year-over-year, standalone adjusted EBIT margin was flat as benefits from productivity and price were offset primarily by investments |
| So, their costs are going down |
Please consider a small donation if you think this website provides you with relevant information